Please assess the completion status of the following clinical trial:

Trial Title: Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Women aged ≥ 18 years~2. Patients with histologically confirmed diagnosis of epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube cancer who received ≥1 prior chemotherapy~3. Patients must be eligible for platin-containing therapy; Patient is defined as platin-sensitive when considered for platin-containing therapy by the investigator. The time frame from end of prior therapy until disease progression alone is not pivotal for study participation. Patients without a platin-containing regimen in the previous line who are also eligible for platin-containing regime are also appropriate for participation~4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2~5. Adequate baseline organ function as defined as~   * Leucocytes \> 3.0 x 109/l~  * Platelet count \> 100 x 109/l~  * Absolute neutrophil count (ANC) ≥1500/mm3~  * Haemoglobin ≥ 9 g/dl~  * Alkaline Phosphatase (AP) ≤ 2.5 × ULN (consider hepatic isoenzymes 5 nucleotidase or gamma glutamyl transpeptidase (GGT), if the elevation could be osseous in origin)~  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN~  * Creatinine-Clearance ≥ 60 ml/min (MDRD formula or Cockroft \& Gault formula)~  * Serum creatinine ≤ 1.5 mg/dl~  * Creatine phosphokinase (CPK) ≤ 2.5 × ULN~  * Total bilirubin \< ULN~6. Women of childbearing potential should use contraceptives or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study medication or be surgically sterile.~7. Adequate cardiac function defined as left ventricular ejection fraction (LVEF) ≥ 50% as determined by echocardiogram~8. Patients must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up assessments and procedures.~Exclusion criteria~1. Only malignancies, which influence the prognosis~2. Any unstable or serious concurrent condition (e.g. active infection requiring systemic therapy).~3. Chemotherapy or radiation therapy or tumor embolization within 2 weeks prior to the first dose of study drug or planned during study participation.~4. Patients who have refractory disease. Refractory disease is defined if relapse occurs \<4 months after beginning of platin-containing therapy.~5. Hypersensitivity to the active substance or to any of the excipients of study drug~6. Findings from ECG and/or assessment of LVEF which indicate an anthracycline-related cardiotoxic process which contradicts administration of liposomal doxorubicin in accordance with the requirements of the SmPC of PLD.~7. Biological therapy, immunotherapy, hormonal therapy or treatment with an investigational agent within 14 days (for bevacizumab, 30 days) prior to the first dose of study drug.~8. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study~9. Participation in another clinical study with experimental therapy within the 30 days before start of and during treatment. Participation in a non-interventional study should be discussed with sponsor and NC beforehand.~10. Patients in a closed institution according to an authority or court decision (AMG § 40, Abs. 1 No. 4)~11. Patients who are depending on the sponsor/CRO or investigational site as well as on the investigator.~12. Pregnancy or lactation period, or planning to become pregnant within 7 months after the end of treatment.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): PLD followed by Trabectedin. Treatment is repeated every 3 weeks for 6 cycles or until disease progression.
- Arm B (Type: EXPERIMENTAL): * Carboplatin/PLD~* Carboplatin/Gemcitabine~* Carboplatin/Paclitaxel Patients will be treated for 6 cycles or until PD, unacceptable toxicity or patient's wish to discontinue, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues